These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 24746758)

  • 1. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
    Dogan I; Kawabata S; Bergbower E; Gills JJ; Ekmekci A; Wilson W; Rudin CM; Dennis PA
    Lung Cancer; 2014 Jul; 85(1):1-6. PubMed ID: 24746758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
    Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
    Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G; Liu C; Sun B; Zhou C; Zhang Z; Wang P
    Oncol Rep; 2014 Jul; 32(1):341-7. PubMed ID: 24842595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
    Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
    Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
    Tabara K; Kanda R; Sonoda K; Kubo T; Murakami Y; Kawahara A; Azuma K; Abe H; Kage M; Yoshinaga A; Tahira T; Hayashi K; Arao T; Nishio K; Rosell R; Kuwano M; Ono M
    PLoS One; 2012; 7(7):e41017. PubMed ID: 22815900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.
    Hong Z; Cao X; Li N; Zhang Y; Lan L; Zhou Y; Pan X; Shen L; Yin Z; Luo L
    Br J Pharmacol; 2014 Jun; 171(11):2842-53. PubMed ID: 24471765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
    Sakuma Y; Nishikiori H; Hirai S; Yamaguchi M; Yamada G; Watanabe A; Hasegawa T; Kojima T; Niki T; Takahashi H
    Lab Invest; 2016 Apr; 96(4):391-8. PubMed ID: 26752745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
    Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
    Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
    Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
    J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination.
    Kuo MH; Lee AC; Hsiao SH; Lin SE; Chiu YF; Yang LH; Yu CC; Chiou SH; Huang HN; Ko JC; Chou YT
    Cancer Res; 2020 Oct; 80(20):4426-4438. PubMed ID: 32816907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
    Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
    Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer.
    Wang M; Zhao J; Zhang LM; Li H; Yu JP; Ren XB; Wang CL
    J Cancer Res Clin Oncol; 2012 Dec; 138(12):2069-77. PubMed ID: 22821179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
    Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
    Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
    Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
    Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.